JP5069807B2 - - Google Patents

Info

Publication number
JP5069807B2
JP5069807B2 JP87108762A JP10876287A JP5069807B2 JP 5069807 B2 JP5069807 B2 JP 5069807B2 JP 87108762 A JP87108762 A JP 87108762A JP 10876287 A JP10876287 A JP 10876287A JP 5069807 B2 JP5069807 B2 JP 5069807B2
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP87108762A
Other languages
Japanese (ja)
Other versions
JPS62258320A (ja
Inventor
Ingumaru Reyoogureen Kutsuto
Gunnaru Piiruburanto Ooke
Mitsuru Yasumura
Satoshi Morigaki
Minoru Oda
Naohiro Ooishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Tanabe Pharma Corp
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Yoshitomi Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26290693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5069807(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co Ltd, Yoshitomi Pharmaceutical Industries Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of JPS62258320A publication Critical patent/JPS62258320A/ja
Publication of JP5069807B2 publication Critical patent/JP5069807B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP62108762A 1986-04-30 1987-04-30 内服用新規医薬製剤 Granted JPS62258320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB08610572A GB2189698A (en) 1986-04-30 1986-04-30 Coated omeprazole tablets
GB8610572 1986-04-30
SG154294A SG154294G (en) 1986-04-30 1994-10-21 New pharmaceutical preparation for oral use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP3355985A Division JP2740993B2 (ja) 1986-04-30 1991-12-20 内服用新規医薬製剤

Publications (2)

Publication Number Publication Date
JPS62258320A JPS62258320A (ja) 1987-11-10
JP5069807B2 true JP5069807B2 (cg-RX-API-DMAC10.html) 1993-10-01

Family

ID=26290693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP62108762A Granted JPS62258320A (ja) 1986-04-30 1987-04-30 内服用新規医薬製剤
JP3355985A Expired - Lifetime JP2740993B2 (ja) 1986-04-30 1991-12-20 内服用新規医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP3355985A Expired - Lifetime JP2740993B2 (ja) 1986-04-30 1991-12-20 内服用新規医薬製剤

Country Status (35)

Country Link
US (1) US4786505A (cg-RX-API-DMAC10.html)
EP (3) EP0496437B1 (cg-RX-API-DMAC10.html)
JP (2) JPS62258320A (cg-RX-API-DMAC10.html)
KR (1) KR910004579B1 (cg-RX-API-DMAC10.html)
CN (1) CN1020852C (cg-RX-API-DMAC10.html)
AR (1) AR240250A1 (cg-RX-API-DMAC10.html)
AT (3) ATE140387T1 (cg-RX-API-DMAC10.html)
CA (1) CA1292693C (cg-RX-API-DMAC10.html)
CY (1) CY1810A (cg-RX-API-DMAC10.html)
DD (1) DD273197A5 (cg-RX-API-DMAC10.html)
DE (3) DE3751860T2 (cg-RX-API-DMAC10.html)
DK (1) DK169988B1 (cg-RX-API-DMAC10.html)
DZ (1) DZ1077A1 (cg-RX-API-DMAC10.html)
ES (3) ES2091971T3 (cg-RX-API-DMAC10.html)
FI (1) FI90393C (cg-RX-API-DMAC10.html)
GB (1) GB2189698A (cg-RX-API-DMAC10.html)
GR (4) GR890300058T1 (cg-RX-API-DMAC10.html)
HK (2) HK135294A (cg-RX-API-DMAC10.html)
HR (1) HRP920854B1 (cg-RX-API-DMAC10.html)
HU (1) HU196708B (cg-RX-API-DMAC10.html)
IE (1) IE61416B1 (cg-RX-API-DMAC10.html)
IL (1) IL82911A (cg-RX-API-DMAC10.html)
IS (1) IS1917B (cg-RX-API-DMAC10.html)
LT (1) LT3699B (cg-RX-API-DMAC10.html)
LV (2) LV10357B (cg-RX-API-DMAC10.html)
NO (1) NO174239C (cg-RX-API-DMAC10.html)
NZ (1) NZ220096A (cg-RX-API-DMAC10.html)
PH (1) PH25701A (cg-RX-API-DMAC10.html)
PL (1) PL151631B1 (cg-RX-API-DMAC10.html)
PT (1) PT84785B (cg-RX-API-DMAC10.html)
RU (2) RU1820837C (cg-RX-API-DMAC10.html)
SG (1) SG154294G (cg-RX-API-DMAC10.html)
SI (1) SI8710681A8 (cg-RX-API-DMAC10.html)
YU (1) YU46192B (cg-RX-API-DMAC10.html)
ZA (1) ZA872378B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403078A (en) 1992-11-12 1995-04-04 Lucas Industries Public Limited Company Hydraulic braking systems for vehicles

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JPH0737383B2 (ja) * 1988-07-11 1995-04-26 エーザイ株式会社 胃酸分泌抑制剤含有固型製剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
WO1990013286A1 (en) * 1989-05-11 1990-11-15 Chugai Seiyaku Kabushiki Kaisha Oral preparation which can be released at suitable region in intestine
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
TW397686B (en) * 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
TW280770B (cg-RX-API-DMAC10.html) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
CA2180535C (en) * 1994-01-05 2004-03-23 Lindberg, Per Lennart A method for treatment of psoriasis, by omeprazole or related compounds
AU1806895A (en) * 1994-02-23 1995-09-11 Bm Research A/S Controlled release composition
SK281803B6 (sk) * 1994-07-08 2001-08-06 Astra Ab Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SI1078628T1 (sl) * 1994-07-08 2009-04-30 Astrazeneca Ab Večenotska tabletirana dozirna oblika
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
ATE171201T1 (de) * 1994-11-21 1998-10-15 Shell Int Research Bitumenzusammensetzungen
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
GB2316342B (en) * 1995-05-09 2000-01-12 Colorcon Ltd Electrostatic coating
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
CZ352097A3 (cs) 1995-05-09 1998-04-15 Colorcon Limited Způsob a materiál pro elektrostatické potahování jádra farmaceutických tablet
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
DK0859612T3 (da) * 1995-09-21 2003-09-22 Pharma Pass Ii Llc Farmaceutisk sammensætning indeholdende en syre-labil omeprazol og fremgangsmåde til fremstilling deraf
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DK1105105T3 (da) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
NZ511169A (en) * 1998-11-18 2003-06-30 Astrazeneca Ab Process for making substituted sulphinyl heterocycles containing an imidazole moiety
RU2144823C1 (ru) * 1998-11-20 2000-01-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Лекарственное средство, обладающее слабительным действием
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
WO2001028559A1 (en) * 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
GB0002305D0 (en) 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
ES2436523T3 (es) * 2001-03-13 2014-01-02 Endo Pharmaceuticals Inc. Formas de dosificación terapéutica
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
BRPI0210096B1 (pt) 2001-05-30 2015-06-30 Euro Celtique Sa Composição farmacêutica compreendendo bissacodil e poloxâmero, processo para a preparação de composição farmacêutica na forma de cápsula cheia e uso de poloxâmero e bissacodil
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2163241A1 (en) * 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
CN1592610A (zh) 2001-09-28 2005-03-09 麦克内尔-Ppc股份有限公司 改良的释放剂型
ES2392960T3 (es) 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
WO2003074514A1 (en) * 2002-03-05 2003-09-12 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
GB2392839A (en) * 2002-03-08 2004-03-17 Bakulesh Mafatlal Khamar Use of Mycobacterium w in the treatment of tuberculosis
US20030180358A1 (en) * 2002-03-25 2003-09-25 Stumberger Walter William System and method for affecting the pH state of the contents of the distal bowel in mammals
US20050182100A1 (en) * 2002-03-28 2005-08-18 Ola Junghard Method of use
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
WO2004014345A1 (en) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
CA2511540A1 (en) * 2002-12-23 2004-07-22 Celltech Americas, Inc. Acid labile drug compositions
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US20050031696A1 (en) * 2003-04-22 2005-02-10 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
GB2420298B (en) * 2003-06-18 2006-08-23 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
NZ544608A (en) * 2003-07-17 2008-07-31 Reddys Lab Ltd Dr Pharmaceutical compositions having a swellable coating comprising prolamin
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1660052A2 (en) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (en) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd NEW TRANSMUCOSAL ADMINISTRATION SYSTEM
US20070202119A1 (en) * 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
US20070065513A1 (en) * 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
JP2007517038A (ja) * 2003-12-30 2007-06-28 ドクター レディズ ラボラトリーズ リミテッド 薬学的組成物
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
EP1721604A4 (en) * 2004-03-04 2008-04-30 Takeda Pharmaceutical STABLE CAPSULE PREPARATION
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2566655C (en) * 2004-05-25 2013-04-16 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US20060051421A1 (en) * 2004-06-15 2006-03-09 Nava Shterman Stable pharmaceutical formulations of benzimidazole compounds
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
PL1796730T3 (pl) * 2004-09-20 2010-12-31 Ltb4 Sweden Ab Stabilizowany środek farmaceutyczny leukotrienu B4 (LTB4)
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
US20070148151A1 (en) 2005-07-29 2007-06-28 Martin Frink Processes for the manufacture and use of pancreatin
SI1931316T1 (sl) * 2005-08-15 2010-06-30 Solvay Pharm Gmbh Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
KR20080076924A (ko) 2005-12-05 2008-08-20 아스트라제네카 아베 에소메프라졸 비-염 형태의 제조를 위한 신규 방법
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
US8486450B2 (en) 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
JP2009523784A (ja) * 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
BRPI0707325A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc formulação de dosagem de liberação multiparticulada e método para preparação da mesma
RU2490012C2 (ru) * 2006-01-27 2013-08-20 Апталис Фарматех Инк Системы доставки лекарственного средства, содержащие слабощелочной селективный 5-ht3, серотониновый блокатор и органические кислоты
WO2007090113A2 (en) 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
PL2007362T3 (pl) 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
AR056062A1 (es) * 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
ES2511792T3 (es) 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
CA2665841C (en) 2006-10-09 2016-04-05 Charleston Laboratories, Inc. Pharmaceutical compositions
BRPI0717613A2 (pt) * 2006-10-17 2013-10-22 Ranbaxy Lab Ltd Composição em comprimido de múltiplas unidades, processo para o preparo do mesmo e método para inibir a secreção de ácido gástrico
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
PL2124884T3 (pl) 2006-12-22 2020-01-31 Ironwood Pharmaceuticals, Inc. Metody i kompozycje do leczenia zaburzeń przełyku
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DK2079445T3 (en) * 2007-02-20 2016-02-15 Allergan Pharmaceuticals Internat Ltd Stable digestive compositions
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
ES2759626T3 (es) * 2007-05-07 2020-05-11 Evonik Operations Gmbh Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
CA2702356C (en) 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
RU2011103170A (ru) * 2008-06-30 2012-08-10 Мерк Шарп Энд Домэ Корп. (Us) Твердые дозированные составы телкагепанта калия
CN102036654B (zh) * 2008-07-24 2014-05-14 湖南洞庭药业股份有限公司 稳定的非典型抗精神病制剂
WO2010018175A2 (en) * 2008-08-11 2010-02-18 Mepha Ag Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
BRPI0918492A2 (pt) * 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
GB2480042B (en) 2009-02-24 2014-03-12 Ritter Pharmaceuticals Inc Solid oral unit-dosage prebiotic forms and methods of use
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US20130202688A1 (en) * 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
CN103442727B (zh) 2011-02-11 2016-08-10 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
RU2602183C2 (ru) 2011-08-08 2016-11-10 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
GB201117480D0 (en) * 2011-10-10 2011-11-23 Palikaras George Filter
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
AU2013299656C1 (en) 2012-08-07 2017-06-22 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
CN102940611B (zh) * 2012-11-26 2017-02-22 康普药业股份有限公司 一种含有埃索美拉唑镁的肠溶片剂
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
EP3991719A1 (en) 2013-01-15 2022-05-04 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
JP6471100B2 (ja) 2013-02-12 2019-02-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
BR112015026283B1 (pt) 2013-04-23 2023-04-25 Société des Produits Nestlé S.A. Composição multiparticulada, método para fabricação da mesma e uso de uma pluralidade de núcleos com revestimentos entéricos individuais contendo um ou mais ingredientes ativos com base em terpeno
RU2679832C2 (ru) 2013-08-09 2019-02-13 Аллерган Фармасьютикалз Интернэйшнл Лимитед Композиция пищеварительных ферментов, подходящая для энтерального введения
EP3082777A4 (en) * 2013-12-20 2017-06-21 9286-3620 Québec Inc. Protein-based enteric coating for oral dosage forms
CN104337788B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 埃索美拉唑钠肠溶制剂及其制备方法
CN104546786A (zh) * 2013-12-30 2015-04-29 四川迪康科技药业股份有限公司 奥美拉唑肠溶制剂及其制备方法
CN104337789B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 雷贝拉唑钠肠溶制剂及其制备方法
KR101658275B1 (ko) 2014-01-20 2016-09-20 대원제약주식회사 에스오메프라졸 함유 소형 의약정제
US20170216328A1 (en) 2014-04-04 2017-08-03 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
LT3324948T (lt) * 2015-07-17 2023-03-27 BE Pharbel Manufacturing Daugiasluoksnės farmaciniu požiūriu aktyvaus junginio atpalaidavimo mikrodalelės skystoje vaisto formoje
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US20190240187A1 (en) * 2015-11-27 2019-08-08 Symrise Ag Oral preparations with omeprazole or pantoprazole
AU2017206077B2 (en) 2016-01-08 2021-11-18 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
JP7027341B2 (ja) 2016-05-12 2022-03-01 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ａｐｐの正常なプロセシングを促進する化合物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
WO2018183881A1 (en) * 2017-03-31 2018-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceuticals ingredients
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
EP3642206A4 (en) 2017-06-23 2021-04-07 The Regents of The University of California INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
WO2019133884A1 (en) 2018-01-01 2019-07-04 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
RU2694527C1 (ru) 2018-02-06 2019-07-16 Шмуэль Борис Левит Комбинация для регенеративной терапии больных сахарным диабетом 1 типа
EP3610860A1 (en) * 2018-08-15 2020-02-19 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Composition of carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose
CN112839635A (zh) 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR102705165B1 (ko) 2019-01-22 2024-09-11 에오비안 파마슈티컬스, 인크. Mtorc 조절제 및 이의 용도
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
TW202126301A (zh) * 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
CN114828832A (zh) * 2019-12-11 2022-07-29 赢创运营有限公司 用于治疗和预防疾病的剂型
PL4072532T3 (pl) * 2019-12-11 2024-06-10 Evonik Operations Gmbh Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
EP4072533B1 (en) 2019-12-11 2025-01-22 Evonik Operations GmbH Dosage form comprising an alkaline agent and an enteric coating layer
CN114569580B (zh) * 2020-12-02 2024-03-01 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN114569579B (zh) * 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN112919975B (zh) * 2021-04-01 2022-02-11 山东爱福地生物股份有限公司 一种智能调控土壤酸碱度的有机肥的生产工艺
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
CN119522229A (zh) 2022-03-04 2025-02-25 瑞瓦吉尼克斯股份有限公司 广谱氨基糖苷及其用途
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
DE1617615A1 (de) * 1966-05-03 1971-03-25 Merck Patent Gmbh Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4382091A (en) * 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685919A (en) * 1985-03-14 1987-08-11 Ngk Spark Plug Co., Ltd. Artificial joint
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403078A (en) 1992-11-12 1995-04-04 Lucas Industries Public Limited Company Hydraulic braking systems for vehicles

Also Published As

Publication number Publication date
DK215887D0 (da) 1987-04-28
GB2189698A (en) 1987-11-04
ATE84215T1 (de) 1993-01-15
IE61416B1 (en) 1994-11-02
NO174239C (no) 1994-04-06
EP0496437A3 (en) 1992-09-02
YU68187A (en) 1988-12-31
FI871913L (fi) 1987-10-31
GR3007434T3 (cg-RX-API-DMAC10.html) 1993-07-30
EP0247983B1 (en) 1993-01-07
IS3221A7 (is) 1987-10-31
KR870009717A (ko) 1987-11-30
CA1292693C (en) 1991-12-03
IS1917B (is) 2004-03-15
FI90393C (sv) 1994-02-10
ATE140387T1 (de) 1996-08-15
JPH05294831A (ja) 1993-11-09
RU1820837C (ru) 1993-06-07
DE3751860D1 (de) 1996-08-22
DE3783394T2 (de) 1993-05-06
EP0567201A3 (en) 1995-06-07
LV5760A4 (lv) 1996-12-20
DE247983T1 (de) 1990-09-27
DE3783394D1 (de) 1993-02-18
LV10357B (en) 1996-04-20
LT3699B (en) 1996-02-26
NO871790D0 (no) 1987-04-29
EP0247983A2 (en) 1987-12-02
EP0496437B1 (en) 1996-07-17
CY1810A (en) 1995-10-20
GB8610572D0 (en) 1986-06-04
NO174239B (no) 1993-12-27
AU7191287A (en) 1987-11-05
PL265416A1 (en) 1988-07-21
NO871790L (no) 1987-11-02
EP0496437A2 (en) 1992-07-29
HUT43954A (en) 1988-01-28
YU46192B (sh) 1993-05-28
JPS62258320A (ja) 1987-11-10
ES2135443T3 (es) 1999-11-01
GR3032101T3 (en) 2000-03-31
HRP920854B1 (en) 1998-12-31
GR3020734T3 (en) 1996-11-30
KR910004579B1 (ko) 1991-07-06
IE871107L (en) 1987-10-30
HK52897A (en) 1997-05-02
ES2006457T3 (es) 1994-01-01
US4786505A (en) 1988-11-22
HRP920854A2 (en) 1994-10-31
NZ220096A (en) 1990-04-26
LTIP1683A (en) 1995-07-25
LV5760B4 (lv) 1997-06-20
FI871913A0 (fi) 1987-04-29
LV10357A (lv) 1995-02-20
CN87103284A (zh) 1987-11-11
SG154294G (en) 1995-03-17
DK215887A (da) 1987-10-31
GR890300058T1 (en) 1989-06-22
ZA872378B (en) 1987-12-30
DE3751860T2 (de) 1996-11-21
DK169988B1 (da) 1995-04-24
EP0247983A3 (en) 1988-10-19
RU2095054C1 (ru) 1997-11-10
PT84785B (pt) 1989-12-29
EP0567201A2 (en) 1993-10-27
IL82911A (en) 1991-06-30
HK135294A (en) 1994-12-09
JP2740993B2 (ja) 1998-04-15
PL151631B1 (en) 1990-09-28
SI8710681A8 (en) 1996-10-31
AR240250A1 (es) 1990-03-30
PT84785A (en) 1987-05-01
ES2091971T3 (es) 1996-11-16
EP0567201B1 (en) 1999-09-15
DD273197A5 (de) 1989-11-08
CN1020852C (zh) 1993-05-26
HU196708B (en) 1989-01-30
ATE184482T1 (de) 1999-10-15
FI90393B (fi) 1993-10-29
DZ1077A1 (fr) 2004-09-13
ES2006457A4 (es) 1989-05-01
AU601974B2 (en) 1990-09-27
PH25701A (en) 1991-09-18

Similar Documents

Publication Publication Date Title
GR3007434T3 (cg-RX-API-DMAC10.html)
IN171099B (cg-RX-API-DMAC10.html)
AU7131891A (cg-RX-API-DMAC10.html)
IN171107B (cg-RX-API-DMAC10.html)
IN165533B (cg-RX-API-DMAC10.html)
IN170394B (cg-RX-API-DMAC10.html)
IN167979B (cg-RX-API-DMAC10.html)
IN166973B (cg-RX-API-DMAC10.html)
IN168343B (cg-RX-API-DMAC10.html)
GR3005438T3 (cg-RX-API-DMAC10.html)
IN168157B (cg-RX-API-DMAC10.html)
IN169545B (cg-RX-API-DMAC10.html)
AU7354491A (cg-RX-API-DMAC10.html)
AU6562586A (cg-RX-API-DMAC10.html)
AU7131791A (cg-RX-API-DMAC10.html)
BE905135A (cg-RX-API-DMAC10.html)
AU4910985A (cg-RX-API-DMAC10.html)
AU5597686A (cg-RX-API-DMAC10.html)
AU5257190A (cg-RX-API-DMAC10.html)
AU5329886A (cg-RX-API-DMAC10.html)
AU5344086A (cg-RX-API-DMAC10.html)
AU5348186A (cg-RX-API-DMAC10.html)
BE905208A (cg-RX-API-DMAC10.html)
BE905178A (cg-RX-API-DMAC10.html)
BE905236A (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071001

Year of fee payment: 14